Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

licence deal

This page shows the latest licence deal news and features for those working in and with pharma, biotech and healthcare.

Sanofi and Scribe announce in vivo genetic therapy partnership worth over $1.2bn

Sanofi and Scribe announce in vivo genetic therapy partnership worth over $1.2bn

Under the latest deal, Sanofi will gain an exclusive licence to use Scribe’s CRISPR X-Editing genome editing technologies to develop in vivo therapies.

Latest news

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... The deal also includes a licence to

  • Deal Watch October 2016 Deal Watch October 2016

    Astellas has structured its deal almost like a licence with one third of the consideration ($462m) upfront and the remainder in “further contingent milestones” (milestones and possibly royalties) as the product ... The licence deal obtained by Summit

  • Deal Watch May 2016 Deal Watch May 2016

    Building on its 2014 deal with MacroGenics, J&J entered into a licence and collaboration agreement for MGD015 for B-cell malignancies with an upfront fee of $75m and $665m in ... Another deal which has taken a hybrid licence / acquisition format is that

  • Deal Watch January 2016 Deal Watch January 2016

    The original deal was a worldwide exclusive licence for the commercialisation of Afrezza in diabetes, with expected peak sales in the range of $0.6bn to $1.0bn (the first nine ... Licensor/Acquired Acquiror/Partner. Deal Type. Comments. Hline $m. Baxalta/

  • Pharma deals in July 2015 Pharma deals in July 2015

    Biogen also broke the $1bn headline in a licence and collaboration deal with AGTC for gene based therapies to treat ophthalmic diseases. ... A strange coincidence! Licensor/Licensee Acquired / Acquirer. Deal type. Product/Technology. Headline $m.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
fox&cat

Fox&cat is an award-winning healthcare communications agency which creates inspirational campaigns and programmes that exceed expectations. Priding itself on delivering...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...

Quick links